Pulmonx Corp (NASDAQ:LUNG)
| Market Cap | 77.72M+3.4% |
| Revenue (ttm) | 87.44M-3.4% |
| Net Income | -48.12M+15.5% |
| EPS | -1.15+19.6% |
| Shares Out | 42.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 379,731 |
| Open | 1.75 |
| Previous Close | 1.78 |
| Day's Range | 1.75 - 1.91 |
| 52-Week Range | 1.13 - 2.89 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 10.00(+443.48%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About LUNG
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$LUNG stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LUNG holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LUNG's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LUNG Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LUNG Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LUNG patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LUNG from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LUNG
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $2.74M |
| VXFVanguard Extended Market ETF | $1.20M |
| IWCiShares Micro-Cap ETF | $231.27K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $60.00K |
| AVSCAvantis U.S. Small Cap Equity ETF | $23.82K |
| DFMCU.S. Micro Cap Portfolio ETF | $22.09K |
Estimated from each fund’s disclosed top holdings × AUM
LUNG Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LUNG’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score